Trending/NMO

Study shows drug reduces risk of relapse with neuromyelitis optica
ROCHESTER, Minn. — The drug eculizumab, a synthetic antibody that inhibits the inflammatory response, significantly reduced the risk of relapse with neuromyelitis optica spectrum disorder…
Special Topics
Sign up

Social Media Network
A network for digital healthcare communicators

Mayo Clinic Connect
An online patient support community